News & Updates

Prediction model for stage I NSCLC refines follow-up strategy, personalizes therapy
Prediction model for stage I NSCLC refines follow-up strategy, personalizes therapy
12 Jul 2023

A prediction model on disease recurrence for low-risk, resected stage I lung adenocarcinoma can classify postoperative patients with available clinical information and may even aid in personalizing a follow-up strategy and future adjuvant therapy, reports a study.

Prediction model for stage I NSCLC refines follow-up strategy, personalizes therapy
12 Jul 2023
Palliative care for interstitial lung disease more difficult than for lung cancer
Palliative care for interstitial lung disease more difficult than for lung cancer
11 Jul 2023
Eosinophil levels do not influence outcomes with triple combo asthma inhaler
Eosinophil levels do not influence outcomes with triple combo asthma inhaler
07 Jul 2023

Treatment with fixed-dose asthma inhaler combination of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) helps improve lung function and reduce exacerbations as compared with MF/IND and fluticasone/salmeterol (FLU/SAL), regardless of baseline eosinophil levels, according to a post hoc analysis of the IRIDIUM study.

Eosinophil levels do not influence outcomes with triple combo asthma inhaler
07 Jul 2023
Virtual ward feasible home-based care strategy for high-risk COVID-19 patients
Virtual ward feasible home-based care strategy for high-risk COVID-19 patients
07 Jul 2023
Add-on fluvoxamine of no benefit in mild-to-moderate COVID-19
Add-on fluvoxamine of no benefit in mild-to-moderate COVID-19
07 Jul 2023

In the treatment of patients with mild-to-moderate COVID-19, adding fluvoxamine to favipiravir does not appear to prevent disease progression or improve certain outcomes, according to the results of an open-label study.

Add-on fluvoxamine of no benefit in mild-to-moderate COVID-19
07 Jul 2023
COVID outcomes worse in polluted cities
COVID outcomes worse in polluted cities
01 Jul 2023